ArticleOncotarget2017
Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis.Frontiers in endocrinology · 2019Pooled it
- Ultra-processed food consumption and the risk of breast cancer incidence and death: a prospective cohort study.Scientific reports · 2025Article
- Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer.JAMA network open · 2025Article
- Risk factors for breast cancer subtypes by race and ethnicity: a scoping review.Journal of the National Cancer Institute · 2024Article
- Risk factors for breast cancer subtypes by race and ethnicity: A scoping review of the literature.medRxiv : the preprint server for health sciences · 2024Article
- A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.Breast cancer research : BCR · 2023Article
- Article
- Review
- Association of Healthy Diet and Physical Activity With Breast Cancer: Lifestyle Interventions and Oncology Education.Frontiers in public health · 2022Review
- Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity.Frontiers in pharmacology · 2021Article
- Osthole Ameliorates Estrogen Deficiency-Induced Cognitive Impairment in Female Mice.Frontiers in pharmacology · 2021Article
- Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.BMJ (Clinical research ed.) · 2020Observational
- Prescription of hormone replacement therapy prior to and after the diagnosis of gynecological cancers in German patients.Journal of cancer research and clinical oncology · 2020Article
- Development and Validation of Lifestyle-Based Models to Predict Incidence of the Most Common Potentially Preventable Cancers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG).BioMed research international · 2019Article
- Understanding sex differences in the regulation of cancer-induced muscle wasting.Current opinion in supportive and palliative care · 2018Review
- A heartfelt message, estrogen replacement therapy: use it or lose it.American journal of physiology. Heart and circulatory physiology · 2018Review
- A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.Journal of medicinal chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We synthesize the current literatures and use the power of meta-analysis to examine trends on association between hormone replacement therapy (HRT) and the risk of breast cancer (BC). We performed a comprehensive literature search using PubMed, EMBASE, and Web of Science from their inception until Jan 2017. Prospective studies that provided adjusted risk estimates of HRT and BC risk were eligible. Categorical and dose-response meta-analyses followed the PRISMA were conducted using random effects model and restricted cubic spline model, respectively. Forty-seven publications from thirty-five unique studies were included, involving 3,898,376 of participants and 87,845 of BC cases. Compared with non-users, RR for current estrogen-only therapy (ET) users was 1.14 (95% confidence interval (CI) = 1.05-1.22), and for per year increases was 1.02 (95% CI = 1.02-1.02). Moreover, RR for current estrogen plus progestin therapy (EPT) users was 1.76, (95% CI = 1.56-1.96), and for per year increases was 1.08 (95% CI = 1.08-1.08). Dose-response analyses revealed 8-10 years' onset peaks, and indicated residual increased BC risk remained after stopping use of ET regimen rather than for EPT. Effect-modifiers like BMI, duration of use, race/ethnicity, routes of administration were recognized. In Conclusions, current use of EP or EPT and ever use of tibolone are associated with an elevated risk of BC. Compared with slim HRT users and non-users, lower BC risks were found among overweight/obese HRT users and former EPT users, respectively. Both ET and EPT users are associated with higher risk of lobular BC than ductal BC, and more ER-positive than negative BC cases were detected among EPT users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.